NCT05529849 is a Phase 1 clinical trial of TCMCB07 in Cachexia, sponsored by Endevica Bio.

Who is sponsoring NCT05529849?

NCT05529849 is sponsored by Endevica Bio.

What drugs are being tested in NCT05529849?

Interventions in NCT05529849: TCMCB07, Placebo.

Is NCT05529849 still recruiting?

NCT05529849 is currently completed. Last updated 21 February 2024.

Last reviewed 2024-02-21 · How we verify

NCT05529849

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects

Completed Phase 1 Last updated 21 February 2024

What this trial tests

Phase 1 trial testing TCMCB07 in Cachexia in 76 participants. Completed in 20 February 2023.

Timeline

12 July 2022

Primary endpoint
12 December 2022

20 February 2023

Quick facts

Lead sponsor	Endevica Bio
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	76
Start date	12 July 2022
Primary completion	12 December 2022
Estimated completion	20 February 2023
Sites	1 location across United States

Drugs / interventions tested

TCMCB07 — full drug profile →
Placebo

Conditions studied

Cachexia — all drugs for Cachexia →

Sponsor

Endevica Bio — full company profile →

Who can join

Adults 18 to 55, any sex, with Cachexia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will test an experimental drug named TCMCB07 for the treatment of cancer cachexia. Cachexia is a syndrome characterized by weight loss, anorexia, weakness or lack of energy, and anemia. Cachexia occurs in many cancers, usually at the advanced stages of disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cachexia

Currently open trials in the same condition.

NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
NCT07338487 — A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Canc · Phase 1 · recruiting
NCT07288619 — Therapeutic Efficacy of Nutritional Supplementation in Cachexia Associated With Chronic Pulmonary Disease · NA · active not recruiting
NCT06989437 — A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Signif · Phase 2, PHASE3 · recruiting
NCT07130981 — Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients · recruiting

Other Endevica Bio trials

Trials by the same sponsor.

NCT07399015 — Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05529849 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Endevica Bio
Last refreshed: 21 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05529849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing